AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

- (Previously Presented) A compressible dosage form comprising an active cushioning component, wherein the active cushioning component is a bead, granule, particle or pellet and, wherein the active cushioning component comprises;
- a placebo cushioning component comprising a highly-compactable filler, a highly water-absorbing material and water; and
- active-loaded particles; wherein the placebo cushioning component and active-loaded particles are admixed to form an admixture; and the admixture is freeze-dried to form the active cushioning component.
- (Original) The compressible dosage form of claim 1, wherein the placebo cushioning component has a particle size ranging from about 20 μm up to about 2000 μm.
- 3. (Original) The compressible dosage form of claim 2, wherein the placebo cushioning component has a particle size ranging from about 20 µm up to about 1000 µm.
- (Original) The compressible dosage form of claim 3, wherein the placebo cushioning component has a particle size ranging from about 20 μm up to about 500 μm.
- 5. (Currently Amended) The compressible dosage form of claim 1, wherein the active-loaded particles is are present in an amount ranging from about 0.1% to about 97% by weight based on the total weight of the active cushioning component.
- (Currently Amended) The compressible dosage form of claim 1, wherein the
 active-loaded particles is are present in an amount ranging from about 20% to about 90% by
 weight based on the total weight of the active cushioning component.
- (Currently Amended) The compressible dosage form of claim 1, wherein the
 active-loaded particles is are present in an amount ranging from about 40% to about 75% by
 weight based on the total weight of the active cushioning component.

NYI-4103713v5 - 3 -

- (Original) The compressible dosage form of claim 1, wherein the highlycompactable filler is present in an amount ranging from about 5% to about 90% based on the combined weight of highly water-absorbing material and compactable filler.
- (Original) The compressible dosage form of claim 8, wherein the highlycompactable filler is present in an amount ranging from about 5% to about 80% based on the combined weight of highly water-absorbing material and compactable filler.
- 10. (Original) The compressible dosage form of claim 9, wherein the highly-compactable filler is present in an amount ranging from about 5% to about 60% based on the combined weight of highly water-absorbing material and compactable filler.
 - 11. (Original) A tablet comprising the compressible dosage form of claim 1.
 - 12. (Withdrawn) A caplet comprising the compressible dosage form of claim 1.
 - 13. (Withdrawn) A lozenge comprising the compressible dosage form of claim 1.
 - 14. (Withdrawn) A capsule comprising the compressible dosage form of claim 1.
 - 15. (Withdrawn) A cachet comprising the compressible dosage form of claim 1.
- 16. (Withdrawn) A method for preparing a compressible dosage form comprising an active cushioning component, comprising:
- a) combining a highly-compactable filler, a highly water-absorbing material and water to form a placebo cushioning component;
 - b) providing active-loaded particles;
- $\label{eq:component} \mbox{admixing the placebo cushioning component and active-loaded particles to} \\ \mbox{form an admixture; and}$
 - d) freeze-drying the admixture to form the active cushioning component.
- 17. (Withdrawn) The method of claim 16, wherein the freeze-drying is performed until the admixture comprising the placebo cushioning component and active-loaded particles has an amount of water ranging from about from about 0% up to about 20% based on the total weight of the active cushioning component.
- 18. (Withdrawn) The method of claim 17, wherein the freeze-drying is performed until the admixture comprising the placebo cushioning component and active-loaded particles has an amount of water ranging from about from about 0% up to about 15% based on the total weight of the active cushioning component.

NYI-4103713v5 - 4 -

- 19. (Withdrawn) The method of claim 18, wherein the freeze-drying is performed until the admixture comprising the placebo cushioning component and active-loaded particles has an amount of water ranging from about from about 0% up to about 10% based on the total weight of the active cushioning component.
- (Withdrawn) The method of claim 16, wherein step (c) further comprises
 extruding the admixture comprising the placebo cushioning component and active-loaded
 particle.
- (Withdrawn) The method of claim 20, wherein step (c) further comprises spheronizing the admixture comprising the placebo cushioning component and active-loaded particle.
- 22. (Withdrawn) The method of claim 16, wherein the placebo cushioning component has a particle size ranging from about 20 μ m up to about 2000 μ m.
- 23. (Withdrawn) The method of claim 22, wherein the placebo cushioning component has a particle size ranging from about 20 μ m up to about 1000 μ m.
- (Withdrawn) The method of claim 23, wherein the placebo cushioning component has a particle size ranging from about 20 µm up to about 500 µm.
- (Withdrawn) The method of claim 16, wherein step (d) further comprises milling the active cushioning component after freeze-drying.
- (Withdrawn) The method of claim 25, wherein the active cushioning component has a particle size ranging from about 20 μm up to about 2000 μm.
- 27. (Withdrawn) The method of claim 26, wherein the active cushioning component has a particle size ranging from about 20 µm up to about 850 µm.
- (Withdrawn) A method for forming a tablet, comprising compressing the compressible dosage form of claim 1 into a tablet.
- (Withdrawn) A method for forming a caplet, comprising compressing the compressible dosage form of claim 1 into a capsule-shaped tablet.
- (Withdrawn) A method for forming a lozenge, comprising compressing the compressible dosage form of claim 1 into a lozenge.
- (Withdrawn) A method for forming an encapsulated dosage form, comprising adding the compressible dosage form of claim 1 to a capsule.

NYI-4103713v5 - 5 -

- (Withdrawn) A method for forming a cachet comprising, depositing the active cushioning component of claim 1 between two wafers, and joining the wafers.
- 33. (Withdrawn) A compressible dosage form comprising an active cushioning component, wherein the active cushioning component comprises:
- a) a freeze-dried placebo cushioning component comprising a highly-compactable filler and a highly water-absorbing material, and having a particle size ranging from about 20 μ m up to about 2000 μ m; and
- active-loaded particles; wherein the freeze-dried placebo cushioning component and active-loaded particles are admixed to form the active cushioning component.
- 34. (Withdrawn) The compressible dosage form of claim 33, wherein the freezedried placebo cushioning component has a particle size ranging from about 20 μ m up to about 850 μ m.
- 35. (Withdrawn) The compressible dosage form of claim 34, wherein the freezedried placebo cushioning component has a particle size ranging from about 20 μ m up to about 425 um.
- 36. (Withdrawn) A method for preparing a compressible dosage form comprising an active cushioning component, comprising:
- a) combining a highly-compactable filler, a highly water-absorbing material and water to form a placebo cushioning component;
- b) freeze-drying the placebo cushioning component to form a freeze-dried placebo cushioning component;
- c) milling the freeze-dried placebo cushioning component to form a freezedried placebo cushioning component having a particle size ranging from about 20 μm up to about 2000 um;
 - d) providing active-loaded particles; and
- e) admixing the freeze-dried placebo cushioning component having a particle size ranging from about $20\,\mu m$ up to about $2000\,\mu m$ and the active-loaded particles to form the active cushioning component.
- (Withdrawn) The method of claim 36, wherein the freeze-dried placebo cushioning component has a particle size ranging from about 20 μm up to about 850 μm.

NYI-4103713v5 - 6 -

Appl. No. 10/749,339

Attorney Docket No. 11478-014-999

Response dated July 18, 2008

Reply to Office Action mailed on April 18, 2008

38. (Withdrawn) The method of claim 37, wherein the freeze-dried placebo cushioning component has a particle size ranging from about 20 μ m up to about 450 μ m.

NYI-4103713v5 - 7 -